Boswellia serrata extract for the treatment of collagenous colitis. A double-blind, randomized, placebo-controlled, multicenter trial

International Journal of Colorectal Disease

Volumn 22, Issue 12, 2007, Pages 1445-1451

  Madisch, Ahmed ^a   Miehlke, Stephan ^a   Eichele, Otto ^b   Mrwa, Jenny ^a   Bethke, Birgit ^a   Kuhlisch, Eberhard ^a   Bästlein, Elke ^b   Wilhelms, Georg ^b   Morgner, Andrea ^a   Wigginghaus, Bernd ^b   Stolte, Manfred ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b Klinikum Bayreuth ^*

Author keywords

Boswellia serrata extract; Collagenous colitis; Microscopic colitis

Indexed keywords

11 KETO BETA BOSWELLIC ACID; ACETYL 11 OXO BETA BOSWELLIC ACID; ACETYL ALPHA BOSWELLIC ACID; ACETYL BETA BOSWELLIC ACID; ACETYLSALICYLIC ACID; ALPHA BOSWELLIC ACID; BETA BOSWELLIC ACID; BOSWELLIA SERRATA EXTRACT; HERBACEOUS AGENT; LISINOPRIL; LOPERAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PLANT MEDICINAL PRODUCT; SCOPOLAMINE BUTYL BROMIDE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AGED; APPETITE DISORDER; ARTICLE; CHRONIC DIARRHEA; CLINICAL ARTICLE; CLINICAL TRIAL; COLLAGENOUS COLITIS; COLONOSCOPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HYPOGLYCEMIA; MALE; MICROSCOPIC COLITIS; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REMISSION; SHORT FORM 36; SYMPTOM; TREATMENT DURATION; TREATMENT REFUSAL; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, ORAL; AGED; ANTI-INFLAMMATORY AGENTS; BOSWELLIA; CHRONIC DISEASE; COLITIS, COLLAGENOUS; COLON; DIARRHEA; DOUBLE-BLIND METHOD; FEMALE; GASTROINTESTINAL AGENTS; GERMANY; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PLANT EXTRACTS; QUALITY OF LIFE; QUESTIONNAIRES; TIME FACTORS; TREATMENT OUTCOME;

EID: 35148850113     PISSN: 01791958     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00384-007-0364-1     Document Type: Article

References (36)

1. Fernandez-Banares F, Salas A, Forne M, Esteve M, Espinos J, Viver JM (1999) Incidence of collagenous and lymphocytic colitis: A 5-year population-based study. Am J Gastroenterol 94:418-423
2. Bohr J, Tysk C, Eriksson S, Jarnerot G (1995) Collagenous colitis in Orebro, Sweden, an epidemiological study 1984-1993. Gut 37:394-397
3. Agnarsdottir M, Gunnlaugsson O, Orvar KB, Cariglia N, Birgisson S, Bjornsson S, Thorgeirsson T, Jonasson JG (2002) Collagenous and lymphocytic colitis in Iceland. Dig Dis Sci 47:1122-1128
4. Tremaine WJ (2000) Collagenous colitis and lymphocytic colitis. J Clin Gastroenterol 30:245-249
5. Pardi DS (2004) Microscopic colitis. An update. Inflamm Bowel Dis 10:860-870
6. Bohr J, Olesen M, Tysk C, Järnerot G (2000) Collagenous and lymphocytic colitis: A clinical and histopathological review. Can J Gastroenterol 14:943-947
7. Veress B, Lofberg R, Bergman L (1995) Microscopic colitis syndrome. Gut 36:880-886
8. Lazenby AJ, Yardley JH, Giardiello FM, Jessurun J, Bayless TM (1989) Lymphocytic (microscopic) colitis: A comparative histopathologic study with particular reference to collagenous colitis. Hum Pathol 20:18-28
9. Stolte M, Ritter M, Borchard F, Koch-Scherrer G (1990) Collagenous gastroduodenitis on collagenous colitis. Endoscopy 22:186-187
10. Carpenter HA, Tremaine WJ, Batts KP, Czaja AJ (1992) Sequential histologic evaluations in collagenous colitis. Correlations with disease behavior and sampling strategy. Dig Dis Sci 37:1903-1909
11. Armes J, Gee DC, Macrae FA, Schroeder W, Bhathal PS (1992) Collagenous colitis: Jejunal and colorectal pathology. J Clin Pathol 45:784-787
12. Bohr J, Tysk C, Yang P, Danielsson D, Jarnerot G (1996) Autoantibodies and immunoglobulins in collagenous colitis. Gut 39:73-76
13. Jarnerot G, Tysk C, Bohr J et al (1995) Collagenous colitis and fecal stream diversion. Gastroenterology 109:449-455
14. Duerr RH, Targan SR, Landers CJ et al (1991) Anti-neutrophil cytoplasmic antibodies in ulcerative colitis: Comparison with other colitides/ diarrheal illnesses. Gastroenterology 100:1590-1596
15. Beaugerie L, Pardi DS (2005) Review article: Drug-induced microscopic colitis-proposal for a scoring system and review of the literature. Aliment Pharmacol Ther 22:277-284
16. Fine K, Ogunji F, Lee E, Lafon G, Tanzi M (1999) Randomized, double-blind placebo-controlled trial of bismuth subsalicylate for microscopic colitis (abstr.). Gastroenterology 166:A880
17. Baert F, Schmit A, D'Haens G, Dedeurwaerdere F, Louis E, Cabooter M, De Vos M, Fontaine F, Naegels S, Schurmans P, Stals H, Geboes K, Rutgeerts P (2002) Budesonide in collagenous colitis-a double-blind placebo-controlled trial with histological follow-up. Gastroenterology 122:20-25
18. Miehlke S, Heymer P, Bethke B, Bästlein E, Meier E, Bartram HP, Wilhelms G, Lehn N, Dorta G, DeLarive J, Tromm A, Bayerdörffer E, Stolte M (2002) Budesonide treatment for collagenous colitis-a randomized, double-blind, placebo-controlled, multicenter trial. Gastroenterology 123:978-984
19. Bonderup OK, Hansen JB, Birket-Smith L, Vestergaard V, Teglbjaerg PS, Fallingborg J (2003) Budesonide treatment of collagenous colitis: A randomised, double blind, placebo controlled trial with morphometric analysis. Gut 52:248-251
20. Madisch A, Heymer P, Voss C, Wigginghaus B, Bastlein E, Bayerdorffer E, Meier E, Schimming W, Bethke B, Stolte M, Miehlke S (2005) Oral budesonide therapy improves quality of life in patients with collagenous colitis. Int J Colorectal Dis 20:312-316
21. Miehlke S, Madisch A, Bethke B, Stolte M (2005) Time to remission with budesonide in collagenous colitis. Aliment Pharmacol Ther 21:1507-1508
22. Miehlke S, Madisch A, Voss C, Morgner A, Heymer P, Kuhlisch E, Bethke B, Stolte M (2005) Long-term follow-up of collagenous colitis after induction of clinical remission with budesonide. Aliment Pharmacol Ther 22:1115-1119
23. Gupta I, Gupta V, Parihar A, Gupta S, Ludtke R, Safayhi H, Ammon HP (1998) Effects of Boswellia serrata gum resin in patients with bronchial asthma: Results of a double-blind, placebo-controlled, 6-week clinical study. Eur J Med Res 3:511-514
24. Sander O, Herborn G, Rau R (1998) Is H15 (resin extract of Boswellia serrata, "incense") a useful supplement to established drug therapy of chronic polyarthritis? Results of a double-blind pilot study. Z Rheumatol 57(1):11-16
25. Kimmatkar N, Thawani V, Hingorani L, Khiyani R (2003) Efficacy and tolerability of Boswellia serrata extract in treatment of osteoarthritis of knee-a randomized double blind placebo controlled trial. Phytomedicine 10:3-7
26. Gerhardt H, Seifert F, Buvari P, Vogelsang H, Repges R (2001) Therapy of active Crohn disease with Boswellia serrata extract H 15. Z Gastroenterol 39:11-17
27. Gupta I, Parihar A, Malhotra P, Singh GB, Ludtke R, Safayhi H, Ammon HP (1997) Effects of Boswellia serrata gum resin in patients with ulcerative colitis. Eur J Med Res 2:37-43
28. Gupta I, Parihar A, Malhotra P, Gupta S, Ludtke R, Safayhi H, Ammon HP (2001) Effects of gum resin of Boswellia serrata in patients with chronic colitis. Planta Med 67:391-395
29. Chande N, McDonald JW, Macdonald JK (2005) Interventions for treating collagenous colitis. Cochrane Database Syst Rev 19:CD003575
30. Madisch A, Miehlke S, Eichele E, Bethke B, Mrwa J, Wilhelms G, Debus M, Bästlein E, Kuhlisch E, Stolte M (2005) Boswellia Serrata Extract for the Treatment of collagenous colitis: A randomized, double-Blind, placebo-controlled, multicenter Trial. Gastroenterology 128:A581
31. Sailer ER, Schweizer S, Boden SE, Ammon HP, Safayhi H (1998) Characterization of an acetyl-11-keto-beta-boswellic acid and arachidonate-binding regulatory site of 5-lipoxygenase using photoaffinity labeling. Eur J Biochem 256:364-368
32. Safayhi H, Mack T, Sabieray J Anazodo MI, Subramanian LR, Ammon HP (1992) Boswellic acids: Novel, specific, nonredox inhibitors of 5-lipoxygenase. J Pharmacol Exp Ther 261/3:1143-1146
33. Safayhi H, Sailer ER, Ammon HPT (1995) Mechanism of 5-lipoxygenase inhibition by acetyl-11-keto-β-boswellic acid. Mol Pharmacol 47:1212-1216
34. Safayhi H, Sailer ER, Ammon HPT (1996) 5-lipoxygenase inhibition by acetyl-11-keto-β-boswellic acid (AKBA) by a novel mechanism. Phytomedicine 3/1:71
35. Krieglstein CF, Anthoni C, Rijcken EJ, Laukotter M, Spiegel HU, Boden SE, Schweizer S, Safayhi H, Senninger N, Schurmann G (2001) Acetyl-11-keto-beta-boswellic acid, a constituent of a herbal medicine from Boswellia serrata resin, attenuates experimental ileitis. Int J Colorectal Dis 16:88-95
36. Syrovets T, Buchele B, Gedig E, Slupsky JR, Simmet T (2000) Acetyl-boswellic acids are novel catalytic inhibitors of human topoisomerases I and II alpha. Mol Pharmacol 58:71-81